Yondelis . Our Case Suggests that Trabectedin Monotherapy May Represent a Viable Therapeutic Option for Patients with Platinum-Refractory Advanced Ovarian Carcinosarcoma .

Prolonged response to trabectedin in a patient with ovarian carcinosarcoma refractory to adjuvant platinum-taxane .

Edgar Petru, Vassiliki Kolovetsiou, Tina Idris .

Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria
 Online Published: March 24, 2013
Abstract

Background: Carcinosarcoma of the ovary carries an unfavorable prognosis and the optimal chemotherapeutic regimen for this disease is yet to be determined. To the authors´ knowledge, this is the first report of a metastatic ovarian carcinosarcoma successfully treated with trabectedin monotherapy after failure of platinum/taxane-based therapy.

Case report: The case of a platinum-refractory advanced ovarian carcinosarcoma in a 73-year-old female is presented.

After initial tumor debulking, the patient received adjuvant carboplatin and paclitaxel. After 2 cycles, tumor progression occurred. The authors speculated that rapid tumor progression occurred as a consequence of regrowth of sarcomatous elements within the carcinosarcoma. This platinum-refractory disease was treated with single-agent trabectedin 1.5 mg/m2 every three weeks. A prolonged partial response for 13 months along with an acceptable safety profile was achieved.

During this time, the patient was able to perform her daily activities without restrictions.

Conclusion: Our case suggests that trabectedin monotherapy may represent a viable therapeutic option for patients with platinum-refractory advanced ovarian carcinosarcoma.